{"id":"NCT02196701","sponsor":"AbbVie","briefTitle":"Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study","officialTitle":"Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-05","primaryCompletion":"2017-03-17","completion":"2017-03-17","firstPosted":"2014-07-22","resultsPosted":"2018-03-19","lastUpdate":"2018-03-19"},"enrollment":46,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Adalimumab","otherNames":["Humira"]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"Adalimumab Plus Methotrexate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.","primaryOutcome":{"measure":"Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment","timeFrame":"Week 16","effectByArm":[{"arm":"Primary Sub-optimal Responders - ADA + MTX","deltaMin":33.3,"sd":null},{"arm":"Secondary Sub-optimal Responders - ADA + MTX","deltaMin":52.5,"sd":null},{"arm":"Adalimumab + Methotrexate","deltaMin":50,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":46},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Nausea","Bronchitis","Fatigue"]}}